National drug pricing regulator NPPA has asked three pharma companies to ensure availability of Penicillamine, used for treatment of Wilson’s disease, in the market.
The drug is manufactured in India by three companies — Panacea Biotec, VHB Life Sciences and Samarth Life sciences.
“This office has been receiving complains regarding shortage of Penicillamine drug (used for treatment of Wilson’s disease) from different parts of the country for two months,” National Pharmaceutical Pricing authority (NPPA) said.
It has been brought to the notice of NPPA that due to shortage of raw material from China, the supply of Penicillamine has been affected, it added.
“In this regard all the three companies have been asked to ensure sufficient availability of the the said drug in the market,” NPPA said.
Under the provisions of DPCO, 2013, NPPA is mandated to monitor the production and availability of the scheduled formulations and the active pharmaceutical ingredients contained in them, it added.
Manufacturer of scheduled formulations and the APIs contained in them are required to furnish information regarding production/import and sale of drugs specified under the National List of Medicines on quarterly basis, NPPA said.
On September 29, Panacea Biotec, one of the three firms mentioned by the pricing regulator had said in a filing to bourses that it had resumed limited production of Cilamin 250 (Penicillamine) capsule despite shortage of the raw material for the medicine.